Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

证券研究报告 强生口服IL-23拮抗剂申报上市，启动与乌司奴单抗的头 对头研究 生物医药行业 强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PIN ...

Core Insights - The China International Import Expo (CIIE) serves as a crucial platform for global medical technology, showcasing cutting-edge innovations and attracting significant investment in China's healthcare sector [1][5] Group 1: Innovations and Product Launches - Sanofi showcased ten innovative products, including the global debut of cardiovascular drugs, highlighting advancements in targeted therapies for hypertrophic cardiomyopathy [2] - Fosun Pharma presented multiple leading global innovations, including the Marie particle therapy system, which significantly reduces the space and cost of traditional treatment rooms [2] - Abbott introduced over ten debut products, featuring advanced biowearable sensor technology and personalized diagnostic solutions [2] Group 2: Accelerated Approval and Market Entry - The "CIIE Baby" concept illustrates the rapid approval and market entry of innovative medical products in China, with Sanofi's Dupilumab injection exemplifying this trend by evolving through multiple indications over seven years [4][5] - Pfizer displayed 17 "CIIE Babies," emphasizing their commitment to accelerating innovation in China, with a goal of obtaining approvals for 60 innovative drugs and new indications by 2030 [6] Group 3: Investment and Local Production - Roche announced a new biopharmaceutical production base in China with an investment of 2.04 billion yuan, marking a significant step in their localization strategy [7] - Intuitive Surgical's partnership with Fosun Pharma for the Da Vinci surgical robot highlights the trend of exhibitors transitioning to investors, with a new facility in Shanghai set to enhance local production capabilities [9] Group 4: Ecosystem Development and Collaboration - The CIIE fosters collaboration among global pharmaceutical companies, with Sanofi and local biotech firms signing strategic agreements to deepen cooperation in drug development [8] - The event has become a magnet for innovation, with 60% of GE Healthcare's new products being led by Chinese teams, showcasing the growing role of local talent in global healthcare advancements [8]

Core Viewpoint - Sanofi is actively contributing to the "Healthy China" initiative by showcasing innovative drugs and vaccines at the 8th China International Import Expo, focusing on major health issues such as cardiovascular diseases, metabolic disorders, respiratory diseases, and cancer [1][2]. Group 1: Innovative Products and Collaborations - Sanofi presented ten first-in-class or best-in-class innovative products, including two groundbreaking cardiovascular therapies making their global debut: Afikaytai tablets and Pulesiran sodium injection [2][3]. - The company is deepening strategic collaborations with local partners to enhance the pharmaceutical innovation ecosystem in China, exemplified by the establishment of the Sanofi-Kaihui Pharmaceutical Innovation Fund [2][3]. Group 2: Commitment to Local Development - Sanofi has been accelerating the approval and market entry of innovative drugs in China, evidenced by the successful launch of multiple products, including the first targeted therapy for immune-mediated thrombotic thrombocytopenic purpura [4][5]. - The company is transitioning from being an exhibitor to an investor, increasing its investment in local production and innovation, including a recent €1 billion investment in a Beijing insulin raw material project [6].

Core Viewpoint - The China International Import Expo (CIIE) is significantly accelerating the speed at which innovative drugs enter the Chinese market, transforming the landscape for multinational pharmaceutical companies and benefiting countless patients [3][8]. Group 1: Innovative Drug Launches - A groundbreaking drug for delaying the progression of type 1 diabetes, Trelagliptin, made its Asian debut at the CIIE and received approval for market entry in September [10]. - Sanofi's innovative cardiovascular drugs and Gilead Sciences' long-acting HIV prevention drug, Lenacapavir, were showcased at the CIIE, indicating a trend of faster access to top-tier medications for Chinese patients [6][18]. - The "CIIE speed" is exemplified by Sanofi's drug Dupixent, which received approval in China ahead of the U.S. FDA, showcasing a record time for innovative drugs to benefit Chinese patients [11]. Group 2: Market Strategy and Investment - Multinational pharmaceutical companies are shifting from merely introducing products to deeper, full-industry chain strategies in China, with Sanofi establishing China as an independent strategic market unit [20][22]. - Novartis has conducted over 100 clinical trials in China and aims for 90% of new drug registrations to align with global timelines within the next two years [28]. - Gilead Sciences is focusing on synchronizing its research and development projects in China with global efforts, emphasizing the importance of the Chinese market [23][26]. Group 3: CIIE's Spillover Effect - The CIIE is not only expediting drug launches but also creating a "spillover effect" that enhances the overall healthcare landscape in China, allowing for broader access to innovative treatments [15][17]. - Since its inception, Novartis has had over 40 innovative drugs and indications approved in China, accounting for 40% of its total approvals in the country since 1987 [15]. - The CIIE serves as a high-level open platform that fosters consensus, innovation, and collaboration among pharmaceutical companies, ultimately changing the lives of Chinese patients [17].

Group 1 - The China International Import Expo (CIIE) has become a significant platform for global companies to showcase innovations and deepen international cooperation, particularly in the healthcare sector [1] - The eighth CIIE opened on November 5, 2025, in Shanghai, featuring a record number of global product launches and highlighting China's strategic position in the global health industry [1] - Major international medical companies like Siemens Healthineers, GE Healthcare, and Pfizer showcased numerous innovative products, with a focus on "China R&D, global debut" [1][2] Group 2 - GE Healthcare presented nearly 40 innovative products, with 60% led by Chinese teams, marking a record high for the expo [2] - Medtronic's first heart pacing catheter developed in China exemplifies the "local innovation, global sharing" model, with significant local procurement and investments in startups [3] - Pfizer aims to accelerate the approval of 60 innovative drugs in China by 2030, having already achieved over half of this goal [3] Group 3 - AI has become an essential feature in medical products, with Siemens showcasing AI-driven innovations that enhance clinical decision-making and patient care [5][6] - Philips emphasized its commitment to local innovation, with over 95% of its products developed and manufactured in China [4] - The integration of AI in healthcare is expanding from hospitals to home care, with Philips investing significantly in AI and data science [7] Group 4 - The expo highlighted innovative drugs for rare diseases, with Sanofi launching two significant cardiovascular drugs [8] - Gilead Sciences introduced a long-acting HIV prevention drug, achieving a record for global synchronization in its launch [9] - The CIIE has become a vital platform for the rapid introduction of new therapies to benefit Chinese patients [9]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) is held from November 5 to 10 at the National Exhibition and Convention Center in Shanghai [1] - The event showcases 461 new products, technologies, and services, transforming into a global stage for innovation [2] Group 2: Medical and Health Innovations - The medical device and healthcare exhibition area features significant innovations, including Siemens Healthineers' brain-machine interface solution, which integrates advanced imaging and navigation technologies [3] - Sanofi's innovative drug, Tregalizumab, for delaying the progression of Type 1 diabetes, has been approved in China after its debut at the expo [4] - Abbott presents over ten innovative products, including a dynamic blood glucose monitoring system that meets international standards [5] Group 3: Pharmaceutical Developments - GSK introduces several groundbreaking products, including the first approved RSV vaccine and a long-acting treatment for chronic hepatitis B [6] - EssilorLuxottica showcases new products for myopia management and wearable devices, emphasizing innovation in vision health [7] Group 4: Life Sciences and Technology - Illumina presents new solutions for protein detection and gene sequencing, highlighting advancements in life sciences [8][9] - The company emphasizes local manufacturing and partnerships to enhance its technological capabilities in China [8] Group 5: Consumer Goods and Sustainability - LEGO Group unveils five globally launched products inspired by Chinese culture, focusing on sustainability and creativity [10][11] - Kao's freeplus brand showcases its research in amino acid-based skincare, aiming to deepen its market presence in China [11] Group 6: Market Strategies and New Products - Skechers uses the expo as a strategic platform for launching new sports products, reinforcing its commitment to the Chinese market [12][13] - Ausnutria presents 61 products across various nutritional categories, emphasizing innovation and market responsiveness [14]

Core Insights - The 8th China International Import Expo (CIIE) showcases numerous leading companies in the medical device and pharmaceutical sectors, including 11 Fortune 500 pharmaceutical companies and the top 10 global medical device firms, contributing to the "Healthy China" initiative [1] Company Highlights - Medtronic presents over 100 innovative products and solutions at the expo, including the Asia-Pacific debut of the Inceptiv rechargeable closed-loop spinal cord stimulator, recognized by TIME magazine as one of the most groundbreaking innovations of 2024 [3] - Sanofi focuses on cardiovascular, metabolic, respiratory, and oncology fields, showcasing several "first-in-class" or "best-in-class" innovative drugs and vaccines, including the global debut of the cardiovascular drug Afikaitai and the injection of Pulasiran sodium [3][4] - Philips displays nearly 50 innovative products and solutions, including 10 new products making their debut in China and over 10 AI-powered health technology solutions, emphasizing the integration of technology in both professional medical and personal health sectors [6] - Boston Scientific showcases over 80 cutting-edge products in the minimally invasive intervention field, with 22 products transitioning from exhibition to commercial availability, including the world's first male stress urinary incontinence sling and a unique thrombectomy device for carotid artery revascularization [7]

Core Insights - The healthcare industry is demonstrating remarkable resilience in response to changing times, with a projected global market growth of 9% in 2024 driven by innovations in specialized treatments, explosive growth in anti-obesity drugs, and widespread application of AI in healthcare [1] - The China International Import Expo (CIIE) serves as a vital platform for global pharmaceutical companies to integrate deeply with the Chinese market and advance the Healthy China strategy [1][2] Industry Trends - The Chinese government has introduced policies to develop the healthcare industry and encourage innovative drug research, positioning China as a potential global center for biopharmaceutical innovation [2] - Major chronic diseases, such as cardiovascular and chronic kidney diseases, pose significant public health challenges in China, with over 400 million patients affected [2] Innovations and Product Launches - At the CIIE, various pharmaceutical companies showcased innovations across multiple fields, including cardiovascular, metabolic, respiratory, and oncology, highlighting their commitment to addressing major health challenges [1] - Novartis introduced the "Heart and Kidney Guardian Evidence-Based Science Popularization" project, emphasizing the dual role of pharmaceutical companies in drug development and public health education [3] - Sanofi launched two innovative cardiovascular drugs, Aficamten and Plerixafor, at the CIIE, addressing unmet patient needs in the treatment of cardiovascular diseases [3] - Roche presented advancements in blood cancer treatments, including new indications for existing therapies and innovative products for hemophilia [5] Strategic Collaborations - Siemens Healthineers and Novartis signed a strategic cooperation agreement to advance the integration of radioligand therapy and molecular imaging systems for precision treatment of diseases like prostate cancer [19] - Novo Nordisk and the Shanghai Clinical Innovation and Translation Research Institute (ACITS) established a strategic partnership to enhance clinical research and innovation in China [16][17] Public Health Initiatives - The CIIE featured discussions on the application of digital technology and AI in public health, aligning with China's "Healthy China 2030" strategy [21][23] - Pfizer emphasized the role of big data and AI in transforming public health systems and achieving health goals in China [23] Emerging Companies and Products - Viseon Pharmaceuticals showcased two innovative drugs at the CIIE, highlighting its commitment to global innovation and rapid market entry in China [24]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) is showcasing numerous renowned companies in the medical device and pharmaceutical healthcare sector, including 11 Fortune 500 pharmaceutical companies and the top 10 global medical device firms [1] - The event aims to support the "Healthy China" initiative by presenting international leading medical innovations, advanced technologies, and services [1] Group 2: Company Highlights - Medtronic is presenting over 100 innovative products and solutions, including several that are making their debut, such as the Inceptiv rechargeable closed-loop spinal cord stimulator, recognized by TIME magazine as one of the most groundbreaking innovations of 2024 [3] - Sanofi is focusing on cardiovascular, metabolic, respiratory, and oncology fields, showcasing several "first-in-class" or "best-in-class" innovative drugs and vaccines, including the global debut of Afikaytai tablets and Plerixafor sodium injection [3][4] - Philips is displaying nearly 50 innovative products and solutions across precision diagnosis, smart intervention, imaging, and personal health, including 10 new products making their debut in China and over 10 AI-enabled health technology solutions [5] - Boston Scientific is presenting over 80 cutting-edge products in the minimally invasive intervention field, with 22 products transitioning from exhibition to commercial availability, including the world's first male stress urinary incontinence sling and a unique thrombectomy device for transcarotid artery revascularization [5][6] Group 3: Innovation and Technology - Medtronic's Inceptiv system adjusts stimulation in real-time based on spinal biological signals to provide consistent treatment for chronic pain patients [3] - Sanofi's Afikaytai tablets represent a potential "best-in-class" treatment for hypertrophic cardiomyopathy, while Plerixafor sodium injection targets a novel mechanism to manage severe hypertriglyceridemia [4] - Philips' interactive exhibition design allows visitors to experience innovations in cardiovascular care and personal health management, emphasizing the integration of technology into daily life [5] - Boston Scientific is hosting professional forums on stroke prevention, coronary intervention technology, and AI medical applications during the expo, aiming to enhance the accessibility of innovative medical outcomes [6]